Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05100836 · ClinicalTrials.gov registry record
SURPASS Impella 5.5 Study
A clinical trial, sponsored by Abiomed.
- Completed
- Registry status
- 1,017
- Enrollment target
NCT05100836: Completed study, sponsored by Abiomed.
NCT05100836 is a clinical trial that has completed, run by Abiomed. The registered enrollment target is 1,017 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05100836 has completed, sponsored by Abiomed.
- COMPLETED
- Registry status
- 1,017 participants
- Enrollment target
Study Summary
A multi-center, prospective \& retrospective, observational single-arm study of the clinical outcomes up to one year collected from electronic health records of patients which have undergone standard of care implantation of Impella 5.5, regardless of clinical situation or indication. All patients will be enrolled via an IRB-approved Waiver of Informed Consent and HIPAA Authorization. All patients who were supported retrospectively (prior to site IRB approval) with Impella 5.5 at the investigative site will be entered into the SURPASS registry and specified as the retrospective cohort.
Primary Outcome
The rate of patients who survived at Impella 5.5 explant, hospital discharge and follow-up up to 1 year
Interventions
- DEVICE Impella 5.5
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,017 participants |
| Start Date | 2020-09-21 |
| Est. Completion | 2025-05-14 |
What the finished NCT05100836 record still lists
NCT05100836 is an observational study that tracks outcomes without assigning an intervention. Its 1,017 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Impella 5.5 is the first listed.
NCT05100836 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05100836 about?
NCT05100836 is a clinical study titled "SURPASS Impella 5.5 Study". A multi-center, prospective \& retrospective, observational single-arm study of the clinical outcomes up to one year collected from electronic health records of patients which have undergone standard of care implantation of Impella 5.5, regardless of clinical situation or indication. All patients wi...
What is the current status of trial NCT05100836?
This trial is currently completed. The enrollment target is 1,017 participants. The study started on 2020-09-21. Estimated completion is 2025-05-14.
What interventions are being tested in trial NCT05100836?
The interventions under investigation include: Impella 5.5 (DEVICE).
Who is sponsoring clinical trial NCT05100836?
This trial is sponsored by Abiomed, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06549595 · 1,018 participants · Phase 3
A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients
- NCT06608823 · 1,016 participants · NA
ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™
- NCT06146738 · 1,015 participants
The PALSUR-study: Palliative Care Versus Surgery in High-grade Glioma Patients (ENCRAM 2203)
- NCT02178163 · 1,020 participants · NA
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI